I was also at the meeting and as Masila said it was quite positive and a like video presentation will be posted next week. A few things which were of note to me in addition to Masila's note;
The prostate cancer trial (Zen-3694) will be commencing in this quarter as the IND, which was filed in December, received a letter yesterday of "pretty much approval" from the FDA (a few minor modifications need to be made). The trial is for very sick patients who have exhausted other prostate cancer treatments.
Don showed a chart illustrating how well, in the lab, Zen-3694 has worked synergistically with a number of current cancer therapies for a number of cancers and said the fact that it is targeting BRD4 means there are a lot of opportunities for Zen-3694 in oncology as a stand alone or combination therapy.
In "deep" discussions with a Chinese company for regional licensing rights to China.
19 million shares have been sold at $1USD
